Conference Call with Ipca Laboratories Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced Q2FY26 results Consolidated Net total Income up 9% at Rs 2,584.36 crore. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.68% in Q2FY26 as against @ 19.10% in Q2FY25. Consolidated Net Profit at Rs 282.57 crore (after exceptional items) up 23%. Exports Income up 7% at Rs 813.65 crore. Indian formulations income up 8% at Rs 1018.90 crore. Result PDF